… that EPO might improve survival among anemic cancer patients … of anemic renal disease
patients receiving recombinant EPO… the EPO dose was associated with a greater mortality rate …

… However, these are non-licensed indications and we do not … of epoetin for patients with
chemotherapy-associated anaemia and a … in cancer patients with anaemia of chronic disease not …

… with chronic lymphocytic leukaemia, non-Hodgkin’s lymphoma and in patients with a history
of autoimmune disease [D]. Endogenous erythropoietin (EPO) levels may be determined to …

… as determined by FISH markers), particularly in patients with less … in cells from patients with
more advanced disease. These … epoetin alfa) is promising for the treatment of anemia of MDS …

… Recombinant human erythropoietin (rHuEPO) treatment can … but has no change in anaemia
of chronic disease or inflammation. … complications in oncohematological patients significantly …

… In the article are described in detail the methods of pathogenetic correction of anemic
syndrome using parenteral iron preparations, recombinant erythropoietin, indications for their …

… anemia was greater in patients with more advanced disease. … EMA approved indications for
epoetin and darbepoetin alfa. … of biosimilar epoetin alfa in anaemic cancer patients, showed …

… their development changed this disease prognosis. But some of … anemia associated with
anemia by neoplastic infiltration. … and the subcutaneous use of the drug erythropoietin stand out. …

… (increased inflammatory markers: CRP >5.0 mg/L), anemia (<… and systemic effects of
erythropoietin and stem cells in uremia. … He also attended an updating course in Oncohematology …

… erythropoietin (rHuEPO) treatment can increase hemoglobin levels, decreased transfusion
requirements, and improve quality of life in patients with cancer… in anaemia of chronic disease …